Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SNTI

SNTI - Senti Biosciences, Inc. Stock Price, Fair Value and News

$0.94-0.06 (-6.00%)
Market Closed

78/100

SNTI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

78/100

SNTI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SNTI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SNTI Price Action

Last 7 days

-2.1%

Last 30 days

8.1%

Last 90 days

-28.2%

Trailing 12 Months

-70.7%

SNTI RSI Chart

SNTI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SNTI Valuation

Market Cap

24.7M

Price/Earnings (Trailing)

-0.52

Price/Sales (Trailing)

7.22

Price/Free Cashflow

-0.49

SNTI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SNTI Fundamentals

SNTI Revenue

Revenue (TTM)

6.4M

SNTI Earnings

Earnings (TTM)

-47.6M

Earnings Growth (Yr)

37.21%

Earnings Growth (Qtr)

-23.03%

SNTI Profitability

Return on Equity

-585.9%

Return on Assets

-90.31%

Free Cashflow Yield

-203.45%

SNTI Investor Care

Shares Dilution (1Y)

472.95%

Diluted EPS (TTM)

-3.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20244.7M5.4M6.1M6.4M
20234.5M4.0M3.2M4.5M
20223.8M4.4M5.0M4.3M
20211.1M1.7M2.2M2.8M
2020000566.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Senti Biosciences, Inc.

SNTI
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEsentibio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES122

Senti Biosciences, Inc. Frequently Asked Questions

SNTI is the stock ticker symbol of Senti Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Senti Biosciences, Inc. is 24.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, SNTI's PE ratio (Price to Earnings) is -0.52 and Price to Sales (PS) ratio is 7.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNTI PE ratio will change depending on the future growth rate expectations of investors.